MARKET

BVAXF

BVAXF

Biovaxys Technol
OTCMQB
0.102
-0.052
-33.79%
Closed 15:55 05/20 EDT
OPEN
0.130
PREV CLOSE
0.154
HIGH
0.130
LOW
0.065
VOLUME
15.27K
TURNOVER
1.65K
52 WEEK HIGH
0.348
52 WEEK LOW
0.026
MARKET CAP
4.49M
P/E (TTM)
-0.6116
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BVAXF last week (0511-0515)?
Weekly Report · 2d ago
Weekly Report: what happened at BVAXF last week (0504-0508)?
Weekly Report · 05/11 09:31
Weekly Report: what happened at BVAXF last week (0427-0501)?
Weekly Report · 05/04 09:31
BioVaxys study shows MVP-S combo boosts immune response in ovarian cancer model
PUBT · 05/01 12:04
Stocks in play: BioVaxys Technology Corp
Barchart · 05/01 09:39
BioVaxys expects late annual, interim filings after audit delay triggers management trade ban
PUBT · 04/28 21:12
BioVaxys PESCO ovarian cancer trial abstract accepted for presentation at ASCO 2026
PUBT · 04/27 12:10
Weekly Report: what happened at BVAXF last week (0420-0424)?
Weekly Report · 04/27 09:31
More
About BVAXF
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergies, and other immunological diseases. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers and also delivers an innate immune activator and a universal CD4 T cell helper peptide.

Webull offers Biovaxys Technology Corp stock information, including OTCMQB: BVAXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVAXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BVAXF stock methods without spending real money on the virtual paper trading platform.